Search - tctmd.com

Displaying 41 - 50 of 50

Sort: Relevancy | Date

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

December 18, 2018

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

News Daily News

Diabetes Drug Canagliflozin Gets MACE Reduction Indication

November 01, 2018

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

News Daily News

LV Diastolic Dysfunction Linked With Higher Mortality Post-TAVR

Yael L. Maxwell

March 01, 2018

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

News Daily News

First High-Sensitivity Troponin Assay Finally Comes to the United States

January 24, 2017

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.